Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:VERX News 16 December 2025

Vertex, Inc. (VERX) Stock News Today: Latest Price, AI Tax Automation Updates, Analyst Forecasts and Outlook (Dec. 16, 2025)

Vertex, Inc. (VERX) Stock News Today: Latest Price, AI Tax Automation Updates, Analyst Forecasts and Outlook (Dec. 16, 2025)

Vertex, Inc. (NASDAQ: VERX) — the tax technology company (not Vertex Pharmaceuticals, which trades as VRTX) — is back on investors’ radar on Tuesday, December 16, 2025, as shares trade higher intraday and the market continues to digest a year defined by two big themes: cloud migration and a rapidly expanding AI-driven product strategy. As of midday Tuesday, VERX traded at about $20.48, up roughly 5% on the session, after opening near $19.40 and moving between roughly $19.24 and $20.51 with under 1 million shares traded at the time of the snapshot. StockAnalysis That price action is notable mostly because
16 December 2025

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
Go toTop